
Platikem 50mg Infusion
Marketer
Alkem Laboratories Ltd
Salt Composition
Cisplatin (50mg)
Overview Platikem 50mg Infusion
Cisplatin 50mg intravenous infusion is a prescription medication employed in the management of ovarian, cervical, and testicular cancers. Its mechanism of action involves inhibiting or retarding cancerous cell proliferation. Administration is via intravenous injection by a qualified healthcare professional. Dosage frequency and regimen are determined by your physician based on your specific condition and may be adjusted. Adhere strictly to your prescribed dosage; incorrect or excessive use can lead to severe adverse effects. Therapeutic benefits may not be immediately apparent, often requiring weeks or months; discontinue only under medical supervision. Common side effects include injection site inflammation (pain, swelling, redness), nausea, and emesis. Ototoxicity (hearing impairment or damage) is a potential serious complication, necessitating pre- and ongoing audiological assessment. Myelosuppression (reduction in blood cell counts) increasing infection risk is also possible, mandating regular blood tests monitoring hematological parameters and hepatic, renal, and cardiac function. Prior to commencing treatment, disclose any history of kidney disease, as renal function may be compromised. Drug interactions are possible; inform your healthcare provider of all concurrent medications. Use during pregnancy or lactation is contraindicated. Male infertility is a potential consequence; pre-treatment sperm cryopreservation should be considered.
Uses of Platikem 50mg Infusion
Cancers of the ovaries, cervix, and testes.
Major Benefits of Platikem 50mg Infusion:
This medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.
Common Side effects of Platikem 50mg Infusion:
- Injection site reactions (pain, swelling, redness)
- Increased risk of infection
- Ear disorder
- Vomiting
- Nausea
- Decreased blood cells (red cells, white cells, and platelets)
- Renal impairment
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Kidney damage
- Hearing loss
- Ringing in ear
How to use Platikem 50mg Infusion:
This medication will be administered by your healthcare provider; self-medication is strongly discouraged.
How Platikem 50mg Infusion works:
Oncaspar 50mg infusion is a chemotherapeutic agent that disrupts the cancerous cells' genetic blueprint (DNA and RNA), thereby halting their proliferation.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Platikem 50mg Infusion lacks established safety data. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
Administering Platikem 50mg Infusion during pregnancy poses a confirmed risk to fetal development and is therefore contraindicated. In exceptional, life-threatening circumstances, a physician might deem its use justifiable if potential benefits outweigh the known hazards. Always seek medical counsel.
Breast feedingUNSAFE
Administering Platikem 50mg Infusion while breastfeeding is contraindicated. Evidence indicates potential infant toxicity from this medication.
DrivingUNSAFE
Administering Platikem 50mg Infusion may induce adverse reactions, including drowsiness and nausea, potentially impairing driving ability.
KidneyCAUTION
Caution is advised when administering 50mg Platikem Infusion to individuals with impaired renal function; dosage modification may be necessary. A physician's consultation is recommended. Platikem 50mg Infusion is contraindicated in patients exhibiting severe kidney disease.
LiverSAFE IF PRESCRIBED
The use of 50mg Platikem Infusion in patients with hepatic impairment is likely safe. Existing evidence indicates dose modification may be unnecessary; however, physician consultation is advised.
What if you forget to take Platikem 50mg Infusion :
Omit a Platikem 50mg Infusion dose? Seek medical advice immediately.
Facts to Know About Platikem 50mg Infusion
| Label | Value |
|---|---|
| Type of Compound | Platinum-based compounds |
| Addictive | None. |
| Medication Category | Cancer therapeutics |
| Mechanism of Action | Platinum-based anti-cancer agents |
